Publications by authors named "Fernanda Musa"

Claim this Profile
I
Ivermectin and gynecologic cancer: What's the data?
Vaidehi Mujumdar, Marilyn Huang, Lindsey Chippendale Smith, Fernanda Musa

Gynecol Oncol Rep· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial.
Ramez N Eskander, Michael W Sill, Lindsey Beffa, Richard G Moore, Joanie M Hope, Fernanda B Musa

Nat Med· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Health disparities in cervical cancer: Estimating geographic variations of disease burden and association with key socioeconomic and demographic factors in the US.
Tara Castellano, Andrew K ElHabr, Christina Washington, Jie Ting, Yitong J Zhang, Fernanda Musa

PLoS One· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
State of the art endocrine treatments for patients diagnosed with endometrial cancer in 2025.
Fernanda B Musa, Kathleen N Moore, Vivek Podder, Brian M Slomovitz

Curr Opin Obstet Gynecol· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The doc versus the bot: A pilot study to assess the quality and accuracy of physician and chatbot responses to clinical questions in gynecologic oncology.
Mary Katherine Anastasio, Pamela Peters, Jonathan Foote, Alexander Melamed, Susan C Modesitt, Fernanda Musa

Gynecol Oncol Rep· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Health disparities in cervical cancer: Estimating geographic variations of disease burden and association with key socioeconomic and demographic factors in the US.
Tara Castellano, Andrew K ElHabr, Christina Washington, Jie Ting, Yitong J Zhang, Fernanda Musa

PLoS One· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
Ramez N Eskander, Michael W Sill, Lindsey Beffa, Richard G Moore, Joanie M Hope, Fernanda B Musa

N Engl J Med· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Doubling down on the future of gynecologic oncology: The SGO future of the profession summit report.
Stephanie V Blank, Warner K Huh, Maria Bell, Sarah Dilley, Melissa Hardesty, Fernanda Musa

Gynecol Oncol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uterine Sarcomas: How to Navigate an Ever-Growing List of Subtypes.
Molly Roy, Fernanda Musa, Sarah E Taylor, Marilyn Huang

Am Soc Clin Oncol Educ Book· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trends in treatment patterns and costs of care among patients with advanced stage cervical cancer.
Fernanda B Musa, Elizabeth Brouwer, Jie Ting, Naomi R M Schwartz, Andy Surinach

Gynecol Oncol· March 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnosis and Management of Adenocarcinoma in Situ: A Society of Gynecologic Oncology Evidence-Based Review and Recommendations.
Deanna Teoh, Fernanda Musa, Ritu Salani, Warner Huh, Edward Jimenez

Obstet Gynecol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant chemotherapy in patients with advanced endometrial cancer.
Olivia R Khouri, Melissa K Frey, Fernanda Musa, Franco Muggia, Jessica Lee

Cancer Chemother Pharmacol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carboplatin (every 21 days) and divided-dose paclitaxel (days 1, 11): rationale and tolerance in chemotherapy naïve women with high-grade epithelial cancers of Mullerian origin.
David Kudlowitz, Alejandro Velastegui, Fernanda Musa, Franco Muggia

Cancer Chemother Pharmacol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer.
Fernanda Musa, Bhavana Pothuri, Stephanie V Blank, Huichung T Ling, James L Speyer

Gynecol Oncol· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.
Fernanda Musa, Amandine Alard, Gizelka David-West, John P Curtin, Stephanie V Blank

Mol Cancer Ther· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preoperative experience for public hospital patients with gynecologic cancer: Do structural barriers widen the gap?
Melissa K Frey, Haley A Moss, Fernanda Musa, Linda Rolnitzky, Gizelka David-West

Cancer· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cross-Sectional Study of the Impact of a Natural Disaster on the Delivery of Gynecologic Oncology Care.
Gizelka David-West, Fernanda Musa, Melissa K Frey, Leslie Boyd, Bhavana Pothuri

Disaster Med Public Health Prep· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dual mTORC1/2 inhibition in a preclinical xenograft tumor model of endometrial cancer.
Sharmilee Bansal Korets, Fernanda Musa, John Curtin, Stephanie V Blank, Robert J Schneider

Gynecol Oncol· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pharmacokinetic evaluation of topotecan as a cervical cancer therapy.
Fernanda Musa, Stephanie Blank, Franco Muggia

Expert Opin Drug Metab Toxicol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Does the presence of adenomyosis and lymphovascular space invasion affect lymph node status in patients with endometrioid adenocarcinoma of the endometrium?
Fernanda Musa, Melissa K Frey, H Beatrice Im, Marina Chekmareva, Lora H Ellenson

Am J Obstet Gynecol· November 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mucinous histology is a risk factor for nodal metastases in endometrial cancer.
Fernanda Musa, Marilyn Huang, Brandi Adams, Edyta Pirog, Kevin Holcomb

Gynecol Oncol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).
Dennis S Chi, Fernanda Musa, Fanny Dao, Oliver Zivanovic, Yukio Sonoda

Gynecol Oncol· January 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Ovarian pregnancy and a copper intrauterine device.
Justin S Brandt, Fernanda Musa, Xuan Wang, Barry D Shaktman

Rev Obstet Gynecol· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lymph nodes: is total number or station number a better predictor of lymph node metastasis in endometrial cancer?
Marilyn Huang, Manjeet Chadha, Fernanda Musa, Patricia Friedmann, Valentin Kolev

Gynecol Oncol· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Postoperative bowel herniation in a 5-mm nonbladed trocar site.
Marilyn Huang, Fernanda Musa, Caroline Castillo, Kevin Holcomb

JSLS· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis